Abstract:A member of the Janus kinase (JAK) family, Tyrosine Kinase 2 (TYK2), is crucial in mediating various cytokine-signaling pathways such as interleukin-23 (IL23), interleukin-12 (IL12) and type I Interferons (IFN) which contribute to autoimmune disorders (e.g., psoriasis, lupus, and inflammatory bowel disease). Thus, TYK2 represents an attractive target to develop small-molecule therapeutics for the treatment of cytokine-driven inflammatory diseases. Selective inhibition of TYK2 over other JAK isoforms is critical to achieve a favorable therapeutic index in the development of TYK2 inhibitors. However, designing small molecule inhibitors to target the adenosine triphosphate (ATP) binding site of TYK2 kinase has been challenging due to the substantial structural homology of the JAK family catalytic domains. Here, we employed an approach to target the JAK homology 2 (JH2) pseudokinase regulatory domain of the TYK2 protein. We developed a series of small-molecule TYK2 pseudokinase ligands, which suppress the TYK2 catalytic activity through allosteric regulation. The TYK2 pseudokinase-binding small molecules in this study simultaneously achieve high affinity-binding for the TYK2 JH2 domain while also affording significantly reduced affinity for the TYK2 JAK homology 1 (JH1) kinase domain. These TYK2 JH2 selective molecules, although possessing little effect on suppressing the catalytic activity of the isolated TYK2 JH1 catalytic domain in the kinase assays, can still significantly block the TYK2-mediated receptor-stimulated pathways by binding to the TYK2 JH2 domain and allosterically regulating the TYK2 JH1 kinase. These compounds are potent towards human T-cell lines and primary immune cells as well as in human whole-blood specimens. Moreover, TYK2 JH2-binding ligands exhibit remarkable selectivity of TYK2 over JAK isoforms not only biochemically but also in a panel of receptor-stimulated JAK1/JAK2/JAK3-driven cellular functional assays. In addition, the TYK2 JH2-targeting ligands also demonstrate high selectivity in a multi-kinase screening panel. The data in the current study underscores that the TYK2 JH2 pseudokinase is a promising therapeutic target for achieving a high degree of biological selectivity. Meanwhile, targeting the JH2 domain represents an appealing strategy for the development of clinically well-tolerated TYK2 inhibitors that would have superior efficacy and a favorable safety profile compared to the existing Janus kinase inhibitors against autoimmune diseases.

Structure of the pseudokinase–kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition

Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways

Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation

JAK2 and SHP2 Reciprocally Regulate Tyrosine Phosphorylation and Stability of Proapoptotic Protein ASK1.

Structures of an Eph receptor tyrosine kinase and its potential activation mechanism.

Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors

Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F

TYK2: An Upstream Kinase of STATs in Cancer

Tyrosine Kinase 2 Inhibitors: Synthesis and Applications in the Treatment of Autoimmune Diseases

Therapeutic Potential of Tyrosine Kinase 2 in Autoimmunity.

Computational analyses of JAK1 kinase domain: subtle changes in the catalytic cleft influence inhibitor specificity.

Nuclear JAK2: Form and Function in Cancer

Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers

Catalytic Subunit A by Phosphorylating Tyrosine 330 of the Syk Inhibits the Activity of Protein Kinase Signal Transduction :

Structural basis for the autoinhibition of the C-terminal kinase domain of human RSK1.

Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control

A JAK Tyrosine Kinase and Pseudokinase Co-inhibition Strategy Combines Enhanced Potency and On-Demand Activation

Advancements in Tyrosine Kinase-Mediated Regulation of Innate Nucleic Acid Sensing.

Tbk1, A Central Kinase In Innate Immune Sensing Of Nucleic Acids And Beyond

Specific Dephosphorylation of Janus Kinase 2 by Protein Tyrosine Phosphatases.

The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region